74 related articles for article (PubMed ID: 37710166)
1. Immune-Related lncRNA Pairs as Prognostic Signature and Immune-Landscape Predictor in Lung Adenocarcinoma.
Yin Z; Zhou M; Liao T; Xu J; Fan J; Deng J; Jin Y
Front Oncol; 2021; 11():673567. PubMed ID: 35083132
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel potential homologous repair deficiency-associated genes in pancreatic adenocarcinoma via WGCNA coexpression network analysis and machine learning.
Liu C; Fang J; Kang W; Yang Y; Yu C; Chen H; Zhang Y; Ouyang H
Cell Cycle; 2023 Nov; 22(21-22):2392-2408. PubMed ID: 38124367
[TBL] [Abstract][Full Text] [Related]
3. Prediction of prognosis and immunotherapy response with a robust immune-related lncRNA pair signature in lung adenocarcinoma.
Cao K; Liu M; Ma K; Jiang X; Ma J; Zhu J
Cancer Immunol Immunother; 2022 Jun; 71(6):1295-1311. PubMed ID: 34652523
[TBL] [Abstract][Full Text] [Related]
4. A novel immune-related lncRNA signature predicts the prognosis and immune landscape in ccRCC.
Dai L; Pan D; Jin J; Lv W
Aging (Albany NY); 2024 Mar; 16(6):5149-5162. PubMed ID: 38484738
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial energy metabolism-related gene signature as a prognostic indicator for pancreatic adenocarcinoma.
Ma Y; Tang R; Huang P; Li D; Liao M; Gao S
Front Pharmacol; 2024; 15():1332042. PubMed ID: 38572434
[No Abstract] [Full Text] [Related]
6. EIF2Ss, a Novel c-Myc-Correlated Gene Family, is Associated with Poor Prognosis and Immune Infiltration in Pancreatic Adenocarcinoma.
Cao Z; Jing Y; Cheng C; Wang F; Guan M; Zhang K; Jiao J; Ruan L; Chen Z
Front Biosci (Landmark Ed); 2024 Mar; 29(3):119. PubMed ID: 38538250
[TBL] [Abstract][Full Text] [Related]
7. Identification and validation of a novel cuproptosis signature for stratifying different prognostic, immune, metabolic, and therapeutic landscapes in pancreatic adenocarcinoma.
Yan X; Zheng W; Xu FS; Chang HL; Zhang Y; Zhang ZY; Zhang YH
Eur Rev Med Pharmacol Sci; 2024 Mar; 28(5):2024-2050. PubMed ID: 38497885
[TBL] [Abstract][Full Text] [Related]
8. A methylation- and immune-related lncRNA signature to predict ovarian cancer outcome and uncover mechanisms of chemoresistance.
Chen L; Gao W; Lin L; Sha C; Li T; Chen Q; Wei H; Yang M; Xing J; Zhang M; Zhao S; Xu W; Li Y; Long L; Zhu X
J Ovarian Res; 2023 Sep; 16(1):186. PubMed ID: 37674251
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of disulfidptosis-related lncRNAs for predicting prognosis and response of immunotherapy in pancreatic adenocarcinoma.
Guo J; Wang Y; Hou J; Zhao T; Wei Z
Transl Cancer Res; 2024 Mar; 13(3):1336-1350. PubMed ID: 38617527
[TBL] [Abstract][Full Text] [Related]
10. Modeling of new markers for the diagnosis and prognosis of pancreatic cancer based on the transition from inflammation to cancer.
Zhou Y; Huang B; Zhang Q; Yu Y; Xiao J
Transl Cancer Res; 2024 Mar; 13(3):1425-1442. PubMed ID: 38617519
[TBL] [Abstract][Full Text] [Related]
11. Identification and Validation of T-Cell Exhaustion Signature for Predicting Prognosis and Immune Response in Pancreatic Cancer by Integrated Analysis of Single-Cell and Bulk RNA Sequencing Data.
Zhu Y; Tan L; Luo D; Wang X
Diagnostics (Basel); 2024 Mar; 14(6):. PubMed ID: 38535087
[TBL] [Abstract][Full Text] [Related]
12. BCL2L1 is regulated by the lncRNA MIR4435-2HG-miR-513a-5p-BCL2L1 ceRNA axis and serves as a biomarker for pancreatic adenocarcinoma treatment and prognosis.
Zhu R; Zhou H; Chen W; Bai S; Wang X; Liu F
Gene; 2024 May; ():148615. PubMed ID: 38788819
[TBL] [Abstract][Full Text] [Related]
13. An E3 ubiquitin-proteasome gene signature for predicting prognosis in patients with pancreatic cancer.
Yin T; Wen J; Xu S; Chen L; Zhang Z; Pan S; Zhou M; Guo X; Wang M; Gong J; Zhang H; Qin R
Front Immunol; 2023; 14():1332626. PubMed ID: 38304253
[TBL] [Abstract][Full Text] [Related]
14. Signature of gene aberrant alternative splicing events in pancreatic adenocarcinoma prognosis.
Yao J; Tang YC; Yi B; Yang J; Chai Y; Yin N; Zhang ZX; Wei YJ; Li DC; Zhou J
J Cancer; 2021; 12(11):3164-3179. PubMed ID: 33976726
[TBL] [Abstract][Full Text] [Related]
15. Explainable cancer factors discovery: Shapley additive explanation for machine learning models demonstrates the best practices in the case of pancreatic cancer.
Su L; Hounye AH; Pan Q; Miao K; Wang J; Hou M; Xiong L
Pancreatology; 2024 May; 24(3):404-423. PubMed ID: 38342661
[TBL] [Abstract][Full Text] [Related]
16. Large-Scale Machine Learning Analysis Reveals DNA Methylation and Gene Expression Response Signatures for Gemcitabine-Treated Pancreatic Cancer.
Ogunleye A; Piyawajanusorn C; Ghislat G; Ballester PJ
Health Data Sci; 2024; 4():0108. PubMed ID: 38486621
[No Abstract] [Full Text] [Related]
17. Construction of S100 family members prognosis prediction model and analysis of immune microenvironment landscape at single-cell level in pancreatic adenocarcinoma: a tumor marker prognostic study.
Xu ZJ; Li JA; Cao ZY; Xu HX; Ying Y; Xu ZH; Liu RJ; Guo Y; Zhang ZX; Wang WQ; Liu L
Int J Surg; 2024 Mar; ():. PubMed ID: 38498399
[TBL] [Abstract][Full Text] [Related]
18. Construction of a novel signature based on immune-related lncRNA to identify high and low risk pancreatic adenocarcinoma patients.
Li N; Chen J; Yu W; Huang X
BMC Gastroenterol; 2023 Sep; 23(1):312. PubMed ID: 37710166
[TBL] [Abstract][Full Text] [Related]
19. Cuproptosis-related lncRNA scoring system to predict the clinical outcome and immune landscape in pancreatic adenocarcinoma.
Huang Y; Gong P; Su L; Zhang M
Sci Rep; 2023 Nov; 13(1):20870. PubMed ID: 38012210
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
